Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
[14C]SPH3127 Mass Balance Study in Healthy Chinese Males
NCT05593562Phase 2Completed
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Oct 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sitokiren in hypertension (HTN), sponsored by Shanghai Pharmaceuticals Holding Co Ltd. Primary endpoints: Cumulative excretion rate of total radioactive substances in excreta at 240 hours, The concentration of SPH3127 in plasma at 168 hours and 1 more. Started Oct 2022; status: completed.
02
Drugs
sitokiren
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on NCT05593562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05593562.